SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending amidst significant volatility, experiencing sharp declines linked to broader ad tech sector weakness and concerns about OpenAI's potential entry into the advertising market. This price action occurred despite multiple recent analyst upgrades reinforcing the company's AI-powered Axon platform and e-commerce expansion. The community remains divided, with many actively buying the dip while others express concerns about overvaluation and potential market manipulation around options activity.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is trending following news that Madryn Asset Management acquired a 91% stake in the company, with discussions around potential delisting or privatization to reduce costs. This has sparked intense community debate, with many anticipating a massive short squeeze due to the extremely low public float and controlling ownership. However, others are cautioning about a potential pump and dump, concerns over the company's fundamentals, and the risk of further share dilution.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is a major talking point among investors, currently experiencing strong bullish sentiment driven by a widely discussed trade agreement perceived to significantly reduce costs for acquiring essential AI hardware, bolstering its data center expansion. The community is actively speculating about imminent deals with major AI players and is buoyed by recent analyst upgrades, reinforcing IREN's pivotal role in the rapidly growing AI infrastructure landscape.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos ($XTZ) is trending driven by recent positive developments such as a 'Uranium Tokenization Breakthrough' on its Etherlink L2 and enhanced staking accessibility. While these advancements foster strong bullish sentiment and discussions around its potential, the community remains divided amidst persistent skepticism regarding its long-term viability and tokenomics.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is trending due to its new partnership with World Liberty Financial for USD1 payroll and card integration, significantly expanding its real-world utility in on-chain payments. The community is overwhelmingly bullish, highlighting ZBCN's ISO 20022 and MiCA compliance, upcoming Super App launch, and potential expansion onto major blockchains as catalysts for substantial growth.

Wishing Well

WISH Crypto is gaining significant attention as its CoinGecko listing has been processed, generating strong community anticipation for its StockTwits chart to become active. The community is highly bullish on this Solana memecoin's unique deflationary tokenomics, which include monthly burns matching US inflation, and its vision for long-term utility and rewards for dedicated holders. Many perceive WISH as a robust, community-backed movement designed for sustained growth, differentiating it from typical short-term plays.

$LEASH is the second token in the Shiba Inu Ecosystem. It was originally envisioned to be a rebase token tied to the price of DogeCoin. Later, it was decided that Leash would turn off the rebase function (the keys to allow rebase were burnt to ensure this) and continue as a simple ERC-20 Token.   Though simple, the fact that LEASH’s tokenomics are the polar opposite of SHIB makes it even more intriguing.   SHIB was made to have an enormous supply of (1 quadrillion tokens) with half locked away, whereas the supply of Leash is only 107,647 minted tokens.

Doge Killer

LEASH CRYPTO is trending as its community weighs a proposed v2 migration aimed at resolving prior token dilution, igniting polarized sentiment. While many investors express deep frustration over its historical price collapse and perceived ecosystem 'scams,' a bullish segment is actively buying, citing LEASH's extremely limited supply and potential for future utility within Shibarium as catalysts for a significant rebound.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending following a recent 1-for-15 reverse stock split and in anticipation of upcoming Phase 3 trial readouts for myelofibrosis and endometrial cancer. However, community discussion is intensely focused on strong dissatisfaction with current management, citing concerns over significant shareholder value destruction, financial discipline, and the company's cash runway. Many believe a change in leadership is essential for any meaningful turnaround, despite the potential positive impact of successful clinical trial data.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Federal National Mortgage Association ($FNMA) is trending following recent comments from former President Trump regarding a significant mortgage bond purchase directive for the GSEs, aiming to lower housing rates and potentially strengthen their financial position. This action, coupled with revelations about major law firms engaged for a potential deal, has sparked intense community debate between those who see it as a precursor to an imminent IPO or uplisting from conservatorship, and others frustrated by ongoing volatility and past delays. Investors are closely watching for further housing policy announcements from prominent figures, particularly concerning the GSEs' future and potential exit from conservatorship.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is currently a major talking point due to its consistent market cap growth and increasing holder count, attracting significant community attention. Many are anticipating a key announcement, fueling speculation about its future trajectory and potential exchange listings. Simultaneously, there's active discussion among users regarding purchasing accessibility and the asset's overall legitimacy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 12.3% - Should You Sell?

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 12.3% - Time to Sell...

SPRY Makes Bullish Cross Above Critical Moving Average

In trading on Friday, shares of ARS Pharmaceuticals Inc (Symbol: SPRY) crossed above their 200 day moving average of $12.77, changing hands as high as $13.01 per share. ARS Pharmaceuticals Inc shares...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company...

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 3.4% - Time to Buy?

ARS Pharmaceuticals (NASDAQ:SPRY) Trading 3.4% Higher - Here's Why...

ARS Pharmaceuticals (NASDAQ:SPRY) Trading 7.9% Higher - What's Next?

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 7.9% - Should You Buy...

ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 6.3% - Time to Buy?

ARS Pharmaceuticals (NASDAQ:SPRY) Trading 6.3% Higher - What's Next...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Moderate Buy" from Analysts

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the stock...

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8.1% - Here's What Happened

ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 8.1% - What's Next...

Franklin Resources Inc. Sells 28,789 Shares of ARS Pharmaceuticals, Inc. $SPRY

Franklin Resources Inc. trimmed its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 1.5% during the second quarter, according to the company in its most recent disclosure...

ARS Pharmaceuticals (NASDAQ:SPRY) Raised to Hold at Zacks Research

Zacks Research upgraded shares of ARS Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Thursday...

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

Traders are discussing the unwinding of a popular pairs trade involving its key competitor, particularly after recent adverse FDA news for that rival.

Significant short interest, cited at 20.5-21%, is sparking conversations about a potential imminent short squeeze for the stock.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.42	--	--	N/A
Q3 '25	-$0.45	-$0.52	-14.59%	MISSED
Q2 '25	-$0.46	-$0.46	-0.43%	MISSED
Q1 '25	-$0.34	-$0.35	-3.45%	MISSED
Q4 '24	-$0.24	$0.48	302.11%	BEAT

SPRY
ARS Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest SPRY News

SPRYARS Pharmaceuticals Inc